Last reviewed · How we verify
Placebo for Ribavirin
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection).
At a glance
| Generic name | Placebo for Ribavirin |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean rather than direct drug action. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the investigational agent.
Approved indications
- Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection)
Common side effects
Key clinical trials
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012) (PHASE2)
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants (PHASE2)
- Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants (PHASE2)
- A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19 (PHASE2)
- A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection (PHASE3)
- A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Ribavirin CI brief — competitive landscape report
- Placebo for Ribavirin updates RSS · CI watch RSS
- AbbVie portfolio CI